“A.B.C.” of Immunotherapy in Hematological Malignancies...Promise and Perils

Jyoti Bajpai1 Deepa Susan Joy Philip2

1Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
2Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, India

Ind J Med Paediatr Oncol 2024;45:106–114.

Abstract

The treatment landscape of hematological malignancies has been evolving at an extremely fast pace. Hematological malignancies are diverse and distinct from solid tumors. These constitute challenges, which are also unique opportunities for immunotherapy. The five categories of immunotherapies that have found success in the management of hematological malignancies are allogeneic hematopoietic stem cell transplant, monoclonal antibodies and innovative designs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cells, and B cell targeting small immunomodulatory molecules. Allogeneic stem cell transplant rightly called our bluntest weapon is the oldest form of successful immunotherapy. Alternate donor transplants and improvement in supportive care have improved the scope of this immunotherapy option. Among monoclonal antibodies, rituximab forms the prototype on which over a dozen other antibodies have been developed. The bispecific T-cell engager (BiTE) blinatumomab engages cytotoxic CD3 T cells with CD19 acute lymphoblastic leukemia (ALL) cells, which is an effective treatment method for relapsed refractory ALL. Immune checkpoint inhibitors have established their role in hematological malignancies with high PD-L1 expression, including relapsed refractory Hodgkin’s lymphoma and primary mediastinal B cell lymphoma (BCL). Small immunomodulatory drugs targeting the B cell receptor downstream signaling through BTK inhibitors, SYK inhibitors, PI3K inhibitors (idelalisib), and BCL-2 inhibitors (venetoclax), and immunomodulatory imide drugs (lenalidomide) have also emerged as exciting therapeutic avenues in immunotherapy. CAR T cells are one of the most exciting and promising forms of adoptive immunotherapy. CAR T cells are rightly called living drugs or serial killers to keep patients alive. CAR T cells are genetically engineered, autologous T cells that combine the cytotoxicity of T cells with the antigen-binding specificity of CARs. CARs are antigen-specific but major histocompatibility complex/human leukocyte antigen-independent. There are five approved CAR T cell products for the management of relapsed refractory leukemias, lymphoma, and multiple myeloma. The past and present of immunotherapy have been really exciting and the future looks incredibly promising. The challenges include widening the availability and affordability beyond specialized centers, identification of potentially predictive biomarkers of response, and

Keywords
► allogeneic stem cell transplant
► CAR T cells
► hematological malignancies
► immune checkpoint inhibitors
► immunotherapy
► monoclonal antibodies

article published online: 2022-11-28
DOI https://doi.org/10.1055/s-0042-1749321.
ISSN 0971-5851.

© 2022. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited.
(https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

The treatment landscape of hematological malignancies has been evolving at an extremely fast pace. Immunotherapy, the fifth pillar of oncology, is carving a niche for itself in the crowded therapeutic landscape. Harnessing the power of the immune system to fight malignancy has been a dream in oncology. In the recent years, a better understanding of the interaction between the immune system and cancer cells has created novel and powerful forms of immunotherapy. Hematological malignancies are diverse and distinct from solid tumors in many aspects. These constitute challenges that are also unique opportunities for immunotherapy.

In this review, we discuss the past, present, and future of immunotherapy in hematological malignancies and its promise and perils.

Why do Hematological Malignancies Pose Challenges which are also Unique Opportunities for Immunotherapy?

1. All hematological malignancies originate from corrupt immune cells, which are in constant contact with healthy immune cells in the same microenvironment. This makes it conducive to constant immune surveillance.
2. All hematological malignancies are diseases of primary and secondary lymphoid organs. Normal immune cell development and differentiation also happens in the same sites. Hence, malignant cells can hijack the niche that belongs to normal immune cells.
3. Acute leukemia arises from hematopoietic stem cells, leading to deficient hematopoiesis, cytopenia, and immunosuppression.
4. Many hematological malignancies have a low tumor mutational burden.
5. Blood is easily accessible to sample immune cells for modification, cell engineering, and reinfusion.
6. Many hematological malignancies have precursor states which can help in studying the role of immune surveillance.

What are the Immunotherapy Options that have Found Success in Hematological Malignancies?

There are five categories of immunotherapies (A.A.B.B.C.C.) that have found success in the management of hematological malignancies, which will be discussed in this review. [Acronym of A.A.B.B.C.C.]

1. Allogeneic hematopoietic stem cell transplant.
2. Monoclonal Antibodies and innovative designs of ADC and BiTES (bispecific T-cell engager).
3. B cells as ripe targets: small immunomodulatory molecules.
4. Immune Checkpoint inhibitors.
5. CAR T cells (► Fig. 1).

1. Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (AlloHSCT) is the earliest form of successful cancer immunotherapy in hematological malignancies. The first AlloHSCT was performed by Dr. Donnall Thomas in 1968. This still holds today as one of the most curative treatment modalities in hematological malignancies. It is often called the chemotherapist’s bluntest weapon, as it does carpet bombing eradicating both the hematopoietic and immune systems

Fig. 1 The "A.B.C." of immunotherapies in hematological malignancies.
of the patient. This forms an ideal model to take our knowl-
edge forward on immunotherapy.

The proof of principle of sensitivity of graft-versus–leuke-
mia (tumor) effect3,2 comes from the efficacy of AlloHSCT in
refractory disease settings,3,4 the success of donor lympho-
cyte infusion/withdrawal of immunosuppression in relapsed
setting,5 and the use of conditioning regimens (reduced
intensity/non-myeloablative) that depend6 more on the
immunological rationale and less on chemotherapy dose
for disease eradication.

The increasing use of alternate donor transplants and
improvements in nonrelapse mortality with advanced sup-
portive care is improving the outcomes. Haploidentical
donor transplant with posttransplant cyclophosphamide
has outcomes comparable to matched unrelated donor trans-
plants.7,8 These novel strategies have revolutionized the field
of allogeneic stem cell transplant.

2. Monoclonal Antibodies and Innovative Designs
Passive immunotherapy with monoclonal antibodies is one of
the most commonly used forms of immunotherapies in
hematological malignancies. Rituximab, the first Food and
Drug Administration (FDA)-approved monoclonal antibody
in oncology, is a type 1 anti-CD20 antibody used to treat B cell
malignancies. Since then, it has become the prototype for the
development of other monoclonal antibodies.

Monoclonal antibodies9 are developed based on either
lineage-specific antigens (LSAs) or non-LSAs (NLSAs).

• LSAs are antigens specific to different stages of the same
lineage of hematopoietic differentiation like CD20 for B
cells and CD3 for T cells.

• NLSAs are antigens that play important roles in the malign-
ancy transformation of cells and are not restricted to a
specific hematopoietic lineage of cells. These can be onco-
genic receptors or glycoproteins like CD52 for chronic
lymphocytic leukemia and SLAMF7 for multiple myeloma.

Mechanisms of action:

• Antibody-dependent cellular cytotoxicity.

• Antibody-dependent phagocytosis.

• Complement-dependent cytotoxicity.

• Direct cytotoxicity and apoptosis.

3. Bispecific T Cell Engagers and Bispecific Killer Cell
Engagers
Bispecific antibodies are an innovative design in which
single-chain variable fragments of two antibodies are fused
to give specificity for two different antigens.

• BiTE is a type of bispecific antibody, in which one target is T
cell engaging domain with anti-CD3 antibody and the other
target is tumor-associated antigen such as anti-CD19 anti-
body in acute lymphoblastic leukemia (ALL). The binding of
BiTE to two targets mediates a cytolytic synapse resembling
a natural immunological synapse. Blinatumomab, a CD3 ×
CD19 BiTE, is the only FDA-approved BiTE for the treat-
ment of R/R B cell precursor ALL (pre-B-ALL).10–12 Blinatumomab
in relapsed refractory B-ALL with active disease yielded a
complete response (CR) rate of 43%, while patients with
minimal residual disease had a CR rate of 80%. Blinatumo-
mab-based combination immunotherapy is being tested.

• Bispecific killer cell engagers are bispecific antibodies
targeting natural killer cell receptor CD16. They are in
the process of development with the hope of utilizing the
power of the innate immune system.

Table 1 gives a comprehensive list of approved mono-
clonal antibodies used in the treatment of hematological
malignancies.

4. Immune Checkpoint Inhibitors: Checkmate with
Checkpoint Inhibitors
The introduction of immune checkpoint inhibitors (ICIs) as
immunomodulatory antibodies, has gained spotlight in the
management of several solid malignancies like melanoma,
non–small cell lung cancer, renal cell carcinoma, and urothelial
bladder cancers. The primary targets for checkpoint inhibition
have been programmed cell death receptor-1 (PD-1) or pro-
grammed cell death ligand-1 (PD-L1) and cytotoxic T-lympho-
cyte-associated antigen 4 (CTLA-4). They are negative
regulators or brakes of the immune system that help the cancer
cells evade immune surveillance. Their established role
in hematological malignancies is currently limited to tumors
with high PD-L1 expression, including Hodgkin’s lymphoma
(HL) and primary mediastinal B cell lymphoma (PMBCL).

4.1 Why the Success of ICI in Hodgkin’s Lymphoma?
The therapeutic benefit of PD-1 blockade is best demonstrat-
ed in patients with HL.

The unique immunological milieu of HL that could criti-
cally contribute to the success of ICI therapy include:

1. The immunologically hot (or inflamed) tumor microenvi-
ronment (TME) of classical HL (cHL) consists of malignant
Hodgkin Reed-Sternberg cells (less than 1%) and an abun-
cant inflammatory immune cell infiltrate which is differ-
ent from the TME observed in non-HL (NHL).13,14

2. Amplification of 9p24.1 (locus-containing JAK2/PDL1/
PDL2), induces aberrant overexpression of PD-L1 on ma-
ignant cells.15

3. Epstein–Barr virus (EBV) infection contributes to PD-L1
upregulation.16 EBV-positive Hodgkin cases have been
shown to have higher PD-L1 expression levels.17

4.2 Evidence for ICI in Hodgkin’s Lymphoma and PMBCL
The early studies in heavily pretreated Hodgkin’s patients,
receiving either nivolumab18 or pembrolizumab19 were very
encouraging. This led to larger phase 2 trials (CHECKMATE
20520–22 and KEYNOTE-08723 respectively). These two studies
had several similarities, with some significant differences
resulting in variance in approved indications during licensing.
Both studies included three cohorts of patients defined accord-
ing to prior autologous stem cell transplant (ASCT) and bren-
tuximab vedotin (BV) exposure (*Table 2), but only KEYNOTE-
08723 included patients who were transplant-naïve (a cohort
of patients deemed transplant-ineligible, mainly because of
chemo-refractoriness). The overall response rates were similar
in both studies at approximately 70%, with most being partial. CRs were documented in 14 to 32%, depending on the study cohort. The median duration of response ranged from 11 to 25 months. The overall survival rate at 2 years exceeded 85% in all cohorts. These impressive results led to regulatory approvals for patients who had failed ASCT and brentuximab (BV) for both drugs, with additional approval for pembrolizumab in the setting of ASCT ineligibility and failure of BV.

PMBCl shares many histologic and genetic features with HL, including aberrations at 9p24 and overexpression of PD-L1. Objective response rates of approximately 46% were reported in the phase IB KEYNOTE-013 ($n = 21$) and phase II KEYNOTE-170 ($n = 53$) pembrolizumab studies, with a CR rate of 13% in the larger phase II study. Progression-free survival was significantly associated with PD-L1 expression, which in turn was associated with the magnitude of the 9p24 abnormality. As with HL, combination strategies with anti-PD-1 antibodies are also being evaluated.

Unlike cHL and PMBCl, PD-L1 overexpression is not commonly seen on B NHL cells. There is some evidence of 9p24 mutations in primary testicular lymphoma and primary central nervous system diffuse large B cell lymphoma, with selected use in these specific subgroups.

4.3 Approved Indications for Immune Checkpoint Inhibitors in Hematological Malignancies

**Nivolumab**

1. Relapsed and refractory HL post-autologous HSCT (auto-HSCT) and brentuximab.
2. Relapsed HL after three or more lines of therapy including auto-HSCT.

**Pembrolizumab**

1. Relapsed and refractory HL in adults post-auto-HSCT and brentuximab.
2. Pediatric relapsed/refractory HL.
3. Relapsed HL post two or more lines of therapy.
4. PMBCl: adult and pediatric patients with refractory PMBCl, or who have relapsed after two or more prior lines of therapy. (Limitations of Use: it is not recommended for the treatment of PMBCl patients who require urgent cytoreductive therapy.)

4.4 The Challenges in Immune Checkpoint Inhibitors Therapy and Potential Solutions to Overcome Them

1. Antigen presentation: The use of major histocompatibility complex (MHC)-independent treatment options like chimeric antigen receptor T cell therapy (CAR T cell therapy) or BiTE.
2. Tumor-associated macrophages resistance: Anti-cerebrospinal fluid antibodies or phosphatidyl 3-kinase-γ (PI3K) inhibitors.
3. TME: Novel checkpoint inhibitors like LAG-3 (lymphocyte activation gene-3) and TIM-3 (T cell immunoglobulin and mucin-domain containing-3) inhibitors.
4. Genetic and epigenetic factors: Epigenetic therapies like deoxyribonucleic acid methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi).
5. Immunosuppressive metabolites: Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor like epacadostat.
6. Biomarker response: Identify biomarkers beyond PD-1/PDL-1/TMB like serum interferon-γ levels and CD8-positive tumor-infiltrating lymphocytes.

### Table 1 The monoclonal antibodies approved for the treatment of hematological malignancies

| Name            | Target | Indications                      | Approval year | MOA                  | Reference |
|-----------------|--------|----------------------------------|---------------|----------------------|-----------|
| Rituximab       | CD20   | B-NHL, DLBCL, CLL, FL            | 1997, 2006, 2010, 2011 | CDC, ADCC, PCD     | 25–28     |
| Ofatumumab      | CD20   | CLL                              | 2009          | CDC, ADCC, PCD      | 29        |
| Obinutuzumab    | CD20   | CLL, FL                          | 2013, 2016    | CDC, ADCC, PCD      | 30,31     |
| Tafasitamab     | CD19   | DLBCL                            | 2020          | ADCC/ADCP           | 32        |
| Alemtuzumab     | CD52   | CLL                              | 2001          | ADCC/CDC/ADCP      | 33,34     |
| Mogenullzumab   | CCR4   | MF, SS                           | 2018          | ADCC                | 35        |
| Daratumumab     | CD38   | MM                               | 2016          | ADCC/CDC/ADCP      | 36        |
| Isatuximab      | CD38   | MM                               | 2020          | ADCC/CDC/ADCP      | 37        |
| Elotuzumab      | SLAMF7 | MM                               | 2015          | ADCC                | 38        |
| Brentuximab     | CD30   | HL, ALCL                         | 2011, 2018    | ADC                 | 39,40     |
| Moxetumomab     | CD22   | HCL                              | 2018          | ADC                 | 41        |
| Gemtuzumab      | CD33   | AML                              | 2017, 2020    | ADC                 | 42,43     |
| Polatuzumab     | CD79b  | DLBCL                            | 2019          | ADC                 | 44        |

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; ALCL, anaplastic large cell lymphoma; AML, acute myeloid leukemia; B-NHL, B non-Hodgkin’s lymphoma; CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; HCL, hairy cell leukemia; HL, Hodgkin’s lymphoma; MF, mycosis fungoides; MM, multiple myeloma; MOA, monoclonal antibody; PCD, programmed cell death; SS, Sézary syndrome.
5. B Cells Ripe Target Small Molecules

Small immunomodulatory drugs targeting the B cell receptor downstream signaling, like BTK inhibitors, SYK inhibitors, PI3K inhibitors, and BCL-2 inhibitors, have emerged as exciting therapeutic avenues in immunotherapy.

6. CART Cells AS "Living Drugs" OR "Serial Killers" to Keep Patients Alive

CAR T cells are one of the most exciting and promising forms of adoptive immunotherapy. CAR T cells are rightly called living drugs or serial killers to keep patients alive. CAR T cells are genetically engineered, autologous T cells that combine the cytotoxicity of T cells with the antigen-binding specificity of antibodies. CARs are antigen-specific but MHC-independent. They have three domains:

(a) Extracellular domain with two parts:
1. Antigen-binding domain: targets specificity to the product.
2. Spacer: provides flexibility that directs the orientation of the antigen and keeps it away from the cell surface to bind effectively with the antigen.

(b) Transmembrane domain: is to effectively anchor the CAR on the T cell membrane.

(c) Intracellular endodomain: decides the construct of successive generations of CARs with improved cytotoxicity, proliferation, engraftment, and persistence.

6.1 CAR Design and Generations: CARs in Nut and Bolt Phase...

Generation 1 CAR: Signaling domain with only CD3 chain.
Generation 2 CAR: Signaling domain with CD3 and one other costimulatory domain like CD28.
Generation 3 CAR: Signaling domain with CD3 and two other costimulatory domains.
Generation 4 CAR or TRUCK (T cells redirected for antigen-unrestricted cytokine-initiated killing):

- Combines the direct cytotoxicity of CAR T cells with immune modulation of cytokines.

6.2 CAR T Cells on a Test Drive to the Clinic: Cell-Processing Procedure and Steps

1. Harvesting of autologous T cells by leukapheresis.
2. Culture and expansion of T cells.
3. Transduction of T cells with CARs.
4. Quality control and testing of CAR T cells.
5. Administration of CAR T cells to the patient.

Table 2 shows the results of landmark immunotherapy trials that led to the approval of ICIs in HL.

| Patient features | CHECKMATE-205 (nivolumab) | KEYNOTE-087 (pembrolizumab) |
|------------------|--------------------------|-----------------------------|
| Arm A | Arm B | Arm C | Cohort 1 | Cohort 2 | Cohort 3 |
| Failed ASCT, brentuximab-naive | Failed ASCT and brentuximab exposed before/after ASCT | Failed ASCT and brentuximab | Failed ASCT and brentuximab | ASCT ineligible, failed chemo and brentuximab | Failed ASCT, no subsequent brentuximab |
| Number of patients | 63 | 80 | 100 | 69 | 81 | 60 |
| Median age (y) | 33 | 37 | 32 | 34 | 40 | 32 |
| Prior lines of treatment | 2 | 4 | 4 | 4 | 4 | 3 |
| ORR (%) | 65 | 71 | 75 | 77 | 67 | 73 |
| CR rate (%) | 32 | 14 | 20 | 26 | 26 | 32 |
| OS at 2 y (%) | 90 | 86 | 86 | 93 | 91 | 89 |

Abbreviations: ASCT, autologous stem cell transplant; CR, complete response; ORR, objective response rate; PFS, progression-free survival.
2. Stimulation with T cell mitogen (magnetic microbeads coated with mitogenic antibody).
3. Transduction of CARs into T cells with a viral vector.
4. Expansion and culture of T cells.
5. Cryopreservation of CAR T cell product.
6. Lymphodepleting conditioning to patient.
7. Thawing and reinfusion of CAR T cell product to the patient.
8. Monitoring and follow-up.

6.3 Causes of Chimeric Antigen Receptor T Cell Treatment Failure

Failure to Receive the CAR T Cell Product on Time

A significant proportion of patients might fail to receive the CAR T cell product on time due to rapidly progressive disease in the relapsed refractory state, long manufacturing times, and failed manufacture. Possible solutions include shifting CAR T cells earlier in the treatment landscape, improvement in the manufacturing process with shorter times of release of the product, and finally off the shelf allogeneic CAR T cells.

Antigen-Negative Escape

Relapse with antigen-negative disease is the most important reason for treatment failure. This can be targeted with bispecific or trispecific CAR T cells.

Failure of Chimeric Antigen Receptor T Cell Engraftment or Expansion

CD19+ relapse of B-ALL after initial remission occurs due to loss of T cell persistence/engraftment. It is usually due to patient-related factors like age, disease burden, and comorbidities, CAR-related factors like CAR construct with costimulatory molecules, murine ectodomain, and viral vector used for transduction, and fitness of T cell. This could be improved by modified CAR constructs like humanized proteins.

6.4 Toxicity Caused by Chimeric Antigen Receptor T Cells

- Cytokine release syndrome.
- Neurotoxicity or “immune cell-associated neurotoxicity syndrome” (ICANS).
- Off-tumor, on-target toxicity: B cell aplasia and hypogammaglobulinemia.
- Post–CAR cytopenia.

6.5 Future Directions for Chimeric Antigen Receptor T Cell Therapy

- Strategies to improve efficacy: Dual antigen targeting with dual signaling/bispecific tandem CAR.
- Strategies to improve specificity: Switchable suicide gene switch CAR and synthetic splitting receptor CAR.
- Strategies to reduce immunotoxicity: Detuning and tuning of CAR T cells.
- Dasatinib to induce reversible inactivation.
- Addressing antigenicity with humanized CARs.
- Universal CARs.
- “Off-The-Shelf” allogeneic CAR T cells.
- TRUCKS.
- Combinational strategies with immune checkpoint inhibitors/AlloHSCT/BiTES.

A summary of the approved CAR T cell products and their landmark trials is given in Table 3.

The summary of immunotherapy options in hematological malignancies is depicted in Fig. 2.

Limitations of this Review

- There is no detailed probing of clinical trials or weighing of evidence that led to the approval of various immunotherapy options.
- There is no elaboration on the side effect profile and management strategies of immunotherapy complications.

Questions and Future Directions in Immunotherapy

- How to widen the availability of immunotherapy options?
- How to screen for potential prognostic and predictive biomarkers of response?
- What is the best combination treatment strategy and rational sequence?
- How to effectively reduce the off-target and on-target toxicities?
- What is the role of gut-microbiome in immune responses?
- What would be the best surrogate endpoints in clinical trials of immunotherapy?
- How is the quality of life of patients affected by immunotherapy?
- How can we make these magic bullets more affordable to our patients?

Conclusion

The past and present of immunotherapy have been really exciting and the future looks incredibly promising. The challenges include widening the availability and affordability beyond specialized centers, experience in the management of complications of these novel agents, and defining appropriate endpoints for response assessment of these agents. The combinational approach of multiple immunotherapies might be the way forward, to complement the treatment strategies, harness the immune system, and improve quantity and quality of life. Hopefully, in the future, we can dream of a synergism of the vision of Dr. Donnall Thomas and Paul Ehrlich, where “the bluntest weapon” may be combined with novel immunotherapies as “true magic bullets.”

Conflict of Interest
None declared.
### References

1. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(03): 555–562.
2. Weiden PL, Flourny N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300(19):1068–1073.
3. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010;28(23):3730–3738.
4. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol 2004;22(22):4532–4540.
Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018;32(08):1768–1777

Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379(9825):1508–1516

FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients; 2020. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(02):155–165

Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371(16):1507–1517

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531–2544

Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(01):45–56

Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331–1342

Abramson JS, Palomba ML, Gordon IJ, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396(10254):839–852

Jacobson C, Chavez J, Sehgal A, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood 2020;136:40–41